Skip to content

Evommune EVMN Proceeds From Issuance Of Private Placement

Proceeds From Issuance Of Private Placement at other companies

Evommune
 logo
Evommune EVMN
$8M
Evommune
 logo
Evommune EVMN
$8M
Navitas Semiconductor Corporation logo
Navitas Semiconductor CorporationNVTS
$25M
Vor Biopharma logo
Vor BiopharmaVOR
$75M
Archer Aviation logo
Archer AviationACHR
$0-100%
SoundHound AI, Inc. logo
SoundHound AI, Inc.SOUN
$0-100%

Other financials

Income statement

See full
Revenue$1.6M+3.5%
Gross profit$961.1K+10.9%
Operating income-$682.8K-2,027%
Net income-$7.0M-5,414%
EPS (diluted)-$0.36-1,700%

Balance sheet

See full
Cash & equivalents$1.1M+401%
Total debt$2.0M
Total equity-$4.5M-3,048%
Total assets$7.2M

Cash flow

See full
Operating cash flow-$424.6K-341%
CapEx$1.0-99.8%
Free cash flow-$2.7M-4,996%

Valuation

See full
Market cap$848.59M+39.5%
Enterprise value$849.52M
P/S127.3×

Profitability

See full
Gross margin53.7%
Operating margin-30.7%
Net margin-90.1%

Returns & leverage

See full
Return on equity275.7%
Debt / equity1.4×
Current ratio1.2×

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfPrivatePlacement.

The official record: Evommune ’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's proceeds from issuance of private placement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evommune 's proceeds from issuance of private placement?
Evommune (EVMN) reported proceeds from issuance of private placement of $8M in Q4 2025.
What does proceeds from issuance of private placement mean?
The total cash proceeds received by the company from the sale of securities directly to private investors rather than through a public offering. This metric indicates the company's ability to raise capital outside of public markets and its reliance on private funding sources.